Candel Therapeutics, Inc.
CADL · Nasdaq · United States
Share price · CADL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CADL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Nov 2026-26.1%
- 3 Nov 2026+8.6%
- 11 Sep 2026-6.9%
- 13 Aug 2026+10.5%
- 4 May 2026+16.4%
Nothing announced by CADL that day or the session before.
- 20 Apr 2026+13.3%
Nothing announced by CADL that day or the session before.
- 17 Apr 2026+23.4%
Nothing announced by CADL that day or the session before.
- 20 Feb 2026-14.2%
- 20 Jan 2026-7.5%
Nothing announced by CADL that day or the session before.
- 16 Jan 2026+7.7%
Nothing announced by CADL that day or the session before.
Share of unusual movement by asset
For each asset, the share of CADL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Herpes simplex virus thymidine kinase (HSV-tk) gene productGene therapy / editing | Non-Small Cell Lung Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
February 2027 (1)
What to watch
2031 (1)
October 2031 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $16M | $204M | $22M-$23M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $20M | $202M | $39M-$17M operating cash flow | report ↗ |
| 2026-Q1 | — | $9.8M | $195M | $8.9M-$18M operating cash flow | report ↗ |
| 2025-Q3 | — | $8.5M | $87M | $11M-$10M operating cash flow | report ↗ |
| 2025-Q2 | — | $7.0M | $101M | $4.8M-$8.9M operating cash flow | report ↗ |
| 2025-Q1 | — | $4.0M | $92M | —-$8.6M operating cash flow | report ↗ |
| 2024-Q3 | — | $5.4M | $17M | $11M-$6.6M operating cash flow | report ↗ |
| 2024-Q2 | — | $5.0M | $22M | $22M-$6.2M operating cash flow | report ↗ |
| 2024-Q1 | — | $4.1M | $26M | $8.2M-$8.4M operating cash flow | report ↗ |
| 2023-Q3 | — | $5.8M | $43M | $8.4M-$8.8M operating cash flow | report ↗ |
| 2023-Q2 | — | $5.9M | $52M | $9.6M-$7.2M operating cash flow | report ↗ |
| 2023-Q1 | — | $5.5M | $60M | $8.8M-$11M operating cash flow | report ↗ |
| 2022-Q3 | <$0.1M | $5.4M | $77M | $8.7M-$9.4M operating cash flow | report ↗ |
| 2022-Q2 | <$0.1M | $5.0M | $87M | $4.2M-$7.1M operating cash flow | report ↗ |
| 2022-Q1 | <$0.1M | $5.4M | $95M | $0.9M-$8.1M operating cash flow | report ↗ |
| 2021-Q3 | <$0.1M | $5.3M | $89M | $16M-$6.9M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $30M | $120M | $9.6M-$38M operating cash flow | report ↗ |
Candel Therapeutics reported no revenue for the full year 2025. Research and development spend was $30.496M, up 57.9% YoY, and cash and cash equivalents totaled $119.731M as of December 31, 2025. The full-year net loss was $38.182M.
The company expects existing cash, together with proceeds from its February 2026 follow-on equity offering, to fund operations into Q1 2028. It plans to initiate a pivotal phase 3 trial of aglatimagene (CAN-2409) in non-small cell lung cancer in Q2 2026 and to submit a Biologics License Application for aglatimagene in localized prostate cancer in Q4 2026. The company also received IND clearance for linoserpaturev (CAN-3110) in recurrent high-grade glioma, entered a $130M term loan facility with Trinity Capital, and announced a $100M royalty funding agreement with RTW Investments. The pancreatic cancer program was paused.
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($3.0M), 5 sales ($3.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-03 | Ostrovsky Maria · General Counsel | Award / grant (derivative) | 315,000 | — | — | Form 4 |
| 2026-09-30 | Manning Paul B · director | Award / grant (derivative) | 2,189 | $8.68 | $19K | Form 4 |
| 2026-09-30 | PAPA JOSEPH C · director | Award / grant (derivative) | 1,325 | $8.68 | $11K | Form 4 |
| 2026-09-30 | Loggia Nicoletta · director | Award / grant (derivative) | 380 | $8.68 | $3K | Form 4 |
| 2026-09-11 | Tak Paul Peter · director, Chief Executive Officer | Open-market sale | 59,379 | $10.46 | $621K | Form 4 |
| 2026-09-10 | Tak Paul Peter · director, Chief Executive Officer | Option exercise | 125,000 | $1.55 | $194K | Form 4 |
| 2026-09-10 | Tak Paul Peter · director, Chief Executive Officer | Open-market sale | 220,866 | $11.50 | $2.5M | Form 4 |
| 2026-09-10 | Tak Paul Peter · director, Chief Executive Officer | Option exercise (derivative) | 125,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 114 reporting institutions held 43.4M shares ($212.5M, 55.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 10,987,017 | $53.8M |
| 2 | RTW INVESTMENTS, LP | 6,422,018 | $31.5M |
| 3 | ACORN CAPITAL ADVISORS, LLC | 3,497,948 | $17.2M |
| 4 | BlackRock, Inc. | 3,109,042 | $15.2M |
| 5 | Saturn V Capital Management LP | 2,896,588 | $14.2M |
| 6 | Portolan Capital Management, LLC | 2,894,325 | $14.2M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2,462,757 | $12.1M |
| 8 | Vestal Point Capital, LP | 1,125,000 | $5.5M |
| 9 | MILLENNIUM MANAGEMENT LLC | 1,060,086 | $5.2M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,035,435 | $5.1M |
| 11 | Halter Ferguson Financial Inc. | 904,051 | $4.4M |
| 12 | STATE STREET CORP | 818,558 | $4.0M |
| 13 | HEIGHTS CAPITAL MANAGEMENT, INC | 775,000 | $3.8M |
| 14 | Sands Capital Alternatives, LLC | 405,837 | $2.0M |
| 15 | NORTHERN TRUST CORP | 323,154 | $1.6M |